Intersect ENT Inc. announced a landmark win for its flagship Propel drug-eluting implant for treatment of chronic sinusitis.
The Palo Alto, Calif.-based company’s device claims to be the first of a new category of devices offering localized, controlled steroid delivery directly to sinus tissue.